Clear Street Group Inc. Invests $57.82 Million in Tempus AI, Inc. $TEM

Clear Street Group Inc. acquired a new position in Tempus AI, Inc. (NASDAQ:TEM) in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 716,406 shares of the company’s stock, valued at approximately $57,821,000. Tempus AI makes up approximately 0.2% of Clear Street Group Inc.’s holdings, making the stock its 27th biggest holding.

Several other large investors have also recently added to or reduced their stakes in TEM. Cranbrook Wealth Management LLC acquired a new position in Tempus AI during the 3rd quarter worth $25,000. GAMMA Investing LLC bought a new position in shares of Tempus AI in the third quarter worth $28,000. Allworth Financial LP increased its holdings in shares of Tempus AI by 5,000.0% during the second quarter. Allworth Financial LP now owns 459 shares of the company’s stock valued at $29,000 after purchasing an additional 450 shares during the period. Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI during the third quarter valued at $38,000. Finally, Tsfg LLC raised its stake in shares of Tempus AI by 1,515.2% during the third quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after purchasing an additional 500 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on TEM. Morgan Stanley reduced their price objective on shares of Tempus AI from $85.00 to $70.00 and set an “overweight” rating for the company in a report on Tuesday, March 3rd. Wall Street Zen downgraded shares of Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Mizuho initiated coverage on shares of Tempus AI in a research note on Thursday, February 19th. They issued an “outperform” rating and a $100.00 price target for the company. JPMorgan Chase & Co. decreased their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Finally, Robert W. Baird initiated coverage on shares of Tempus AI in a research note on Tuesday, February 17th. They set an “outperform” rating and a $59.00 price objective on the stock. Eight analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $78.62.

Insider Buying and Selling

In other Tempus AI news, EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $60.31, for a total value of $660,334.19. Following the completion of the sale, the executive vice president directly owned 126,918 shares of the company’s stock, valued at approximately $7,654,424.58. This represents a 7.94% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Eric P. Lefkofsky sold 13,587 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $802,312.35. Following the transaction, the chief executive officer owned 1,989,626 shares of the company’s stock, valued at approximately $117,487,415.30. This trade represents a 0.68% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 570,143 shares of company stock worth $35,595,055 in the last ninety days. Insiders own 26.27% of the company’s stock.

Tempus AI Trading Up 0.9%

Shares of TEM stock opened at $49.98 on Friday. The stock has a 50-day simple moving average of $59.20 and a 200 day simple moving average of $71.70. Tempus AI, Inc. has a fifty-two week low of $36.22 and a fifty-two week high of $104.32. The stock has a market capitalization of $8.93 billion, a P/E ratio of -35.45 and a beta of 5.29. The company has a quick ratio of 3.00, a current ratio of 3.13 and a debt-to-equity ratio of 2.52.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.